A Phase 3 interventional study of obinutuzumab (RO5072759) in Lupus Nephritis, sponsored by Zhao Minghui. Not yet recruiting at 14 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Zhao Minghui · Phase 3, Interventional, and Treatment
Among 95 studies in Lupus Nephritis with a site in China — 42 open to participants now, 45 under way, 8 of them phase 3. Lupus Nephritis · China.
Among the 95 studies in Lupus Nephritis with a site in China, this one is the 37th largest by planned enrollment of the 87 interventional ones that give a count, is one of 10 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 39 of the 44 other live ones, and was the 94th registered.
340 studies on the registry are indexed under Lupus Nephritis; 135 are open to participants now.
Browse Lupus Nephritis studies →42 of the 95 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Beijing GoBroad Hospital · Sites in China
Beijing Biotech · Sites in China
Nanjing University School of Medicine · Sites in China
China Immunotech (Beijing) Biotechnology Co., Ltd. · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 51 (58%) stop at 75 or younger; 29 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 30 · Phase 3 22 · Phase 4 7
First in 1996; this study’s year is marked. 10 started in 2026.
This study's planned enrollment of 70 is above the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 87 interventional studies, 400 across the 7 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 95 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zhao Minghui as lead sponsor.
Zhao Minghui has 1 study filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
17 of the studies in Lupus Nephritis with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06406205Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | 2027-06 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07236762China Immunotech (Beijing) Biotechnology Co., Ltd.An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | 2026-11-24 |
| NCT07706998Nanjing UniversityApplication of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis | 2026-12-31 |
Among the 95 studies in Lupus Nephritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA：
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Obinutuzumab add on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids (O-triple) in initial active LN patients.
Drug: obinutuzumab (RO5072759)
Patients will receive Obinutuzumab 1000 mg at day1 (week 0) and weeks 2, 24, 26, and 52, in combination with glucocorticoids and MMF.
Proportion of patients who achieve a complete renal response (CRR) at Week 76
Urinary protein-to-creatinine ratio (UPCR) \<0.5 g/g eGFR ≥ 85% of baseline, as calculated using the CKD-EPI equation No occurrence of intercurrent events (rescue therapy, treatment failure, and early study withdrawal are considered as intercurrent events).
Time frame: Baseline, Week 76
The proportion of patients who achieve ORR (CRR or PRR), CRR, PRR, PERR at week 24, week 36, week 52, week 76
Time frame: Baseline week 24, week 36, week 52, week 76
Plan to share: Yes
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Feb 2029, 29 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab